Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
CHM Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume2.58M
Average Volume (3M)2.05M
Market Cap
AU$9.07M
Enterprise ValueAU$14.47M
Total Cash (Recent Filing)AU$22.41M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,268,209,700
10 Day Avg. Volume3,014,500
30 Day Avg. Volume2,054,362
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21654.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Chimeric Therapeutics Ltd. News
PremiumCompany Announcements
Chimeric Therapeutics Lists Options on ASX to Boost Market Engagement
PremiumCompany Announcements
Chimeric Therapeutics Extends Entitlement Offer Deadline
PremiumCompany Announcements
Chimeric Therapeutics Announces Shareholder Structure Analysis
PremiumCompany Announcements
Chimeric Therapeutics Announces New ASX Quotation for OptionsPremiumCompany Announcements
Chimeric Therapeutics Launches $3.2 Million Entitlement OfferPremiumCompany Announcements
Chimeric Therapeutics Announces Proposed Issue of 25 Million Securities
PremiumCompany Announcements
Chimeric Therapeutics Updates Proposed Securities Issue
PremiumCompany Announcements
Chimeric Therapeutics Announces $3.2 Million Entitlement Offer---
Options Prices
Currently, No data available
---
Ownership Overview
12.22% Insiders
―
Mutual Funds
― Other Institutional Investors
87.78% Public Companies and
Individual Investors
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Chimeric Therapeutics Ltd.’s market cap is AU$9.07M.
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Aug 28, 2025 which is in 138 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Feb 28, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 2,268,209,700 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
---
Chimeric Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CHM Sentiment 80%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$800.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-180.09%
Trailing 12-Months
Asset Growth
-30.02%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
---
Biotron Limited
―
Opthea Limited
―
Imugene Limited
―
Patrys Limited
―
Race Oncology Ltd.
―
---